MaxCyte, Inc. (AIM: MXCT)
Market Cap | 310.16M |
Revenue (ttm) | 35.95M |
Net Income (ttm) | -28.03M |
Shares Out | 105.14M |
EPS (ttm) | -0.27 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 3,244 |
Open | 300.00 |
Previous Close | 295.00 |
Day's Range | 290.25 - 300.00 |
52-Week Range | 180.00 - 430.00 |
Beta | n/a |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Sep 20, 2024 |
About MaxCyte
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engin... [Read more]
Financial Performance
In 2023, MaxCyte's revenue was $41.29 million, a decrease of -6.72% compared to the previous year's $44.26 million. Losses were -$37.92 million, 60.9% more than in 2022.
Financial numbers in USD Financial StatementsNews
![](https://cdn.snapi.dev/images/v1/a/z/press10-2628400.jpg)
MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference
ROCKVILLE, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discove...
![](https://cdn.snapi.dev/images/v1/r/h/transcript40-2572589.jpg)
MaxCyte, Inc. (MXCT) Q2 2024 Earnings Call Transcript
MaxCyte, Inc. (NASDAQ:MXCT) Q2 2024 Earnings Call August 6, 2024 4:30 PM ET Company Participants Scott Feinberg - Investor Relations Maher Masoud - President and Chief Executive Officer Doug Swirsky ...
![](https://cdn.snapi.dev/images/v1/n/z/press9-2571575.jpg)
MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance
ROCKVILLE, Md., Aug. 06, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discover...
![](https://cdn.snapi.dev/images/v1/y/u/conf8-2516018.jpg)
MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024
ROCKVILLE, Md., July 09, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discover...
![](https://cdn.snapi.dev/images/v1/q/a/press16-2451412.jpg)
MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference
ROCKVILLE, Md., May 29, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery...
![](https://cdn.snapi.dev/images/v1/b/q/press15-2443228.jpg)
MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development
Legend Biotech obtains license to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support its non-viral engineered pipeline portfolio across a variety of cell types including T ...
![](https://cdn.snapi.dev/images/v1/k/o/transcript10-2425457.jpg)
MaxCyte, Inc. (MXCT) Q1 2024 Earnings Call Transcript
MaxCyte, Inc. (NASDAQ:MXCT) Q1 2024 Earnings Call Transcript May 7, 2024 4:30 PM ET Company Participants Erik Abdow - Investor Relations Maher Masoud - President & Chief Executive Officer Douglas Swi...
![](https://cdn.snapi.dev/images/v1/2/9/press14-2416131.jpg)
MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance
ROCKVILLE, Md., May 07, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery...
![](https://cdn.snapi.dev/images/v1/n/h/conf5-2365010.jpg)
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
ROCKVILLE, Md., April 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discove...
![](https://cdn.snapi.dev/images/v1/f/u/press18-2351848.jpg)
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
Be Biopharma to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform within its Engineered B Cell Medicines programs Be Biopharma to use MaxCyte's Flow Electroporation® technology and E...
![](https://cdn.snapi.dev/images/v1/8/s/transcript2-2321407.jpg)
MaxCyte, Inc. (MXCT) Q4 2023 Earnings Call Transcript
MaxCyte, Inc. (MXCT) Q4 2023 Earnings Call Transcript
![](https://cdn.snapi.dev/images/v1/o/s/press14-2320922.jpg)
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
ROCKVILLE, Md., March 12, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discove...
![](https://cdn.snapi.dev/images/v1/m/v/press19-2307276.jpg)
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
ROCKVILLE, Md., March 04, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discove...
![](https://cdn.snapi.dev/images/v1/o/t/conf2-2269172.jpg)
MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences
ROCKVILLE, Md., Feb. 09, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discover...
![](https://cdn.snapi.dev/images/v1/n/8/press20-2250526.jpg)
MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen's Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers
Wugen to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support its programs for hematologic and solid tumor cancers Wugen to use MaxCyte's Flow Electroporation® technology and...
![](https://cdn.snapi.dev/images/v1/m/d/press10-2240059.jpg)
MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs
Imugene using MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support azer-cel – a potential first-in-class allogeneic CD19 CAR T product candidate for the treatment of blood cancer...
![](https://cdn.snapi.dev/images/v1/a/w/press18-2221120.jpg)
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results
ROCKVILLE, Md., Jan. 08, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discover...
![](https://cdn.snapi.dev/images/v1/u/g/press12-2214548.jpg)
MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline
Lion TCR to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to develop and scale TCR-T cell therapies for solid tumors and viral-related diseases. Lion TCR to use MaxCyte's Flow El...
![](https://cdn.snapi.dev/images/v1/s/z/press16-2212719.jpg)
MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director
ROCKVILLE, Md., Jan. 01, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discover...
![](https://cdn.snapi.dev/images/v1/w/i/press10-2191836.jpg)
MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023
Doug Doerfler, President and CEO, to Retire Effective December 31, 2023; will continue to serve as an advisor to MaxCyte
![](https://cdn.snapi.dev/images/v1/v/8/image-1421515036-2171966.jpg)
MaxCyte May Benefit From Potential Gene Therapy Approval
MaxCyte is a pick-and-shovel play on cell editing technology, but may capture a royalty stream from successful products. Vertex's potential candidate approval in the U.S. could prove a decisive cataly...
![](https://cdn.snapi.dev/images/v1/r/t/press20-2161166.jpg)
MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member
MaxCyte continues supporting the advancement of novel therapeutics and looks to support education and advancement of mRNA medicines MaxCyte continues supporting the advancement of novel therapeutics a...
![](https://cdn.snapi.dev/images/v1/g/h/transcript46-2148890.jpg)
MaxCyte, Inc. (MXCT) Q3 2023 Earnings Call Transcript
MaxCyte, Inc. (NASDAQ:MXCT) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Sean Menarguez - Head of IR Doug Doerfler - President & CEO Douglas Swirsky - CFO Confere...
![](https://cdn.snapi.dev/images/v1/r/l/press14-2148029.jpg)
MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance
ROCKVILLE, Md., Nov. 08, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discover...
![](https://cdn.snapi.dev/images/v1/a/4/conf19-2142473.jpg)
MaxCyte to Participate in Two Upcoming Investor Conferences
ROCKVILLE, Md., Nov. 06, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discover...